Cellect Biotechnology Ltd. – American Depositary Shares (APOP) PT Set at $14.00 by HC Wainwright

Cellect Biotechnology Ltd. – American Depositary Shares (NASDAQ:APOP) has been given a $14.00 target price by investment analysts at HC Wainwright in a note issued to investors on Friday. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 40.14% from the stock’s previous close.

Separately, ValuEngine downgraded shares of Cellect Biotechnology Ltd. – American Depositary Shares from a “hold” rating to a “sell” rating in a research report on Friday, December 1st.

Shares of Cellect Biotechnology Ltd. – American Depositary Shares (APOP) traded up $0.18 during trading hours on Friday, reaching $9.99. 353,406 shares of the company were exchanged, compared to its average volume of 159,485. The firm has a market capitalization of $54.89 and a P/E ratio of -14.33. Cellect Biotechnology Ltd. – American Depositary Shares has a 1 year low of $2.94 and a 1 year high of $13.50.

An institutional investor recently bought a new position in Cellect Biotechnology Ltd. – American Depositary Shares stock. Susquehanna International Group LLP purchased a new stake in shares of Cellect Biotechnology Ltd. – American Depositary Shares (NASDAQ:APOP) in the third quarter, according to its most recent filing with the SEC. The firm purchased 12,764 shares of the company’s stock, valued at approximately $101,000. Susquehanna International Group LLP owned 0.23% of Cellect Biotechnology Ltd. – American Depositary Shares at the end of the most recent quarter. 0.69% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Cellect Biotechnology Ltd. – American Depositary Shares (APOP) PT Set at $14.00 by HC Wainwright” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/05/cellect-biotechnology-ltd-american-depositary-shares-apop-pt-set-at-14-00-by-hc-wainwright.html.

Cellect Biotechnology Ltd. – American Depositary Shares Company Profile

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.

Receive News & Ratings for Cellect Biotechnology Ltd. - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellect Biotechnology Ltd. - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply